Preliminary efficacy of telisotuzumab vedotin (Teliso-V) treatment in the 2L/3L setting in MET gene amplified ( MET Amp), c-Met protein overexpressing (c-Met OE), nonsquamous, non-small cell lung cancer (NSQ NSCLC): Retrospective analysis of LUMINOSITY

被引：3
|
作者：
Camidge, D. Ross
Goldman, Jonathan
Vasilopoulos, Athan
Ansell, Peter
Xia, Summer
Bolotin, Ellen
Looman, Jim
Ratajczak, Christine
Noon, Elysa
Lu, Shun
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-CT214
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT214
引用
收藏
页数：3
相关论文
共 37 条
  • [1] c-Met expression and response to telisotuzumab vedotin (teliso-v) in patients with non-small cell lung cancer.
    Heist, Rebecca Suk
    Motwani, Monica
    Barlesi, Fabrice
    Goldman, Jonathan Wade
    Kelly, Karen
    Sun, Yan
    Wu, Jun
    Bach, Bruce Allen
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] Patient-reported outcomes (PROs) from a phase 2 trial of telisotuzumab vedotin (Teliso-V) in c-Met-overexpressing, EGFR wild type, non-squamous non-small cell lung cancer (c-Met OE, EGFR WT, NSq NSCLC)
    Lu, S.
    Bar, J.
    Girard, N.
    Xu, Q.
    Sen, R.
    Ratajczak, C.
    Ng, S.
    Xia, S.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2023, 34
  • [3] Patient-reported outcomes (PROs) in the LUMINOSITY trial: Evaluating telisotuzumab vedotin (Teliso-V) in patients (Pts) with c-Met protein overexpressing (OE), EGFR wildtype, non-squamous non-small cell lung cancer (NSQ NSCLC)
    Girard, N.
    Lu, S.
    Bar, J.
    Xu, Q.
    Ng, S.
    Sen, R.
    Majd, Z.
    Nsiah, I.
    Ratajczak, C.
    Xia, M. S.
    Karve, S.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2024, 35 : S836 - S836
  • [4] Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met-overexpressing (OE) advanced non-small cell lung cancer (NSCLC).
    Camidge, D. Ross
    Bar, Jair
    Horinouchi, Hidehito
    Goldman, Jonathan W.
    Moiseenko, Fedor Vladimirovich
    Filippova, Elena
    Cicin, Irfan
    Bradbury, Penelope Ann
    Daaboul, Nathalie
    Tomasini, Pascale
    Ciuleanu, Tudor-Eliade
    Planchard, David
    Moskovitz, Mor
    Girard, Nicolas
    Jin, Janet Yikai
    Dunbar, Martin
    Bolotin, Ellen
    Looman, Jim
    Ratajczak, Christine
    Lu, Shun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Phase 2 Study of Telisotuzumab Vedotin (Teliso-V) in Previously Treated c-MET plus Non-Small Cell Lung Cancer: Trial in Progress
    Ocampo, C.
    Wu, J.
    Dey, J.
    Sun, Z.
    Motwani, M.
    Reddy, A.
    Parikh, A.
    Hay, J.
    Komarnitsky, P.
    Bach, B.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S646 - S646
  • [6] Phase Ib study of telisotuzumab vedotin (Teliso-V) and osimertinib in patients (Pts) with advanced EGFR-mutated (Mut), c-Met overexpressing (OE) non-small cell lung cancer (NSCLC): Final efficacy and safety updates
    Horinouchi, H.
    Cho, B. C.
    Camidge, D. R.
    Goto, K.
    Tomasini, P.
    Li, Y.
    Vasilopoulos, A.
    Brunsdon, P.
    Hoffman, D.
    Shi, W.
    Blot, V.
    Goldman, J. W.
    ANNALS OF ONCOLOGY, 2023, 34 : S1670 - S1670
  • [7] Telisotuzumab vedotin (Teliso-V) in combination with osimertinib in patients with advanced EGFR-mutated, c-met overexpressing, non-small cell lung cancer (NSCLC): Safety and efficacy results from phase Ib study
    Horinouchi, H.
    Goldman, J. W.
    Cho, B. C.
    Tomasini, P.
    Dunbar, M.
    Hoffman, D.
    Parikh, A.
    Blot, V.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2022, 33 : S1592 - S1592
  • [8] Telisotuzumab Vedotin (teliso-v) Monotherapy in Patients With Previously Treated c-Met+ Advanced Non-Small Cell Lung Cancer
    Camidge, D. R.
    Moiseenko, F.
    Cicin, I.
    Horinouchi, H.
    Filippova, E.
    Bar, J.
    Lu, S.
    Tomasini, P.
    Ocampo, C.
    Sullivan, D.
    Maag, D.
    Goldman, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S875 - S875
  • [9] Circulating tumour DNA (ctDNA) analysis in patients (pts) with non-small cell lung cancer (NSCLC) treated with telisotuzumab vedotin (teliso-v), an antibody-drug conjugate targeting c-Met
    Heist, R. S.
    Motwani, M.
    Naumovski, L.
    Wu, J.
    Bach, B. A.
    Lu, X.
    Kelly, K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [10] Telisotuzumab vedotin (teliso-v) monotherapy in patients with previously treated c-Met+ advanced non-small cell lung cancer.
    Camidge, D. Ross
    Moiseenko, Fedor
    Cicin, Irfan
    Horinouchi, Hidehito
    Filippova, Elena
    Bar, Jair
    Lu, Shun
    Tomasini, Pascale
    Ocampo, Christopher
    Sullivan, Danielle
    Maag, David
    Goldman, Jonathan W.
    CANCER RESEARCH, 2021, 81 (13)
1234